Experienced in Adult Soft Tissue Sarcoma

Dr. Laith Abushahin

Oncology
Baylor Scott & White Health
Texas Oncology, P.A.
3410 Worth Street, Suite 400, 
Dallas, TX 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
20 Years of Experience
Experienced in Adult Soft Tissue Sarcoma
Baylor Scott & White Health
Texas Oncology, P.A.
3410 Worth Street, Suite 400, 
Dallas, TX 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Laith Abushahin is an Oncologist in Dallas, Texas. Dr. Abushahin has been practicing medicine for over 20 years and is rated as an Experienced provider by MediFind in the treatment of Adult Soft Tissue Sarcoma. His top areas of expertise are Pancreatic Cancer, Familial Pancreatic Cancer, Cholangiocarcinoma (Bile Duct Cancer), and Familial Colorectal Cancer.

His clinical research consists of co-authoring 18 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has participated in 1 clinical trial in the study of Adult Soft Tissue Sarcoma.

Graduate Institution
University Of Jordan, 2006.0
Residency
Internal Medicine Medical Oncology, University of Arizona College of Medicine GME
Specialties
Oncology
Licenses
Internal Medicine in IA
Fellowships
Medical Oncology, Baylor University Medical Center
Hospital Affiliations
Baylor University Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Baylor Scott & White Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
FirstCare
  • HMO
Friday Health

Accepted plan types not found. Please verify directly with the provider.

Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
Superior Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

Texas Oncology, P.A.
3410 Worth Street, Suite 400, Dallas, TX 75246
Call: 972-449-0540

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Pilot Study of Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel in Metastatic Pancreatic Adenocarcinoma
A Pilot Study of Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel in Metastatic Pancreatic Adenocarcinoma
Enrollment Status: Recruiting
Publish Date: February 07, 2025
Intervention Type: Drug
Study Drugs: Gemcitabine, Nab-paclitaxel
Study Phase: Phase 2
A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients With Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma
A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients With Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma
Enrollment Status: Suspended
Publish Date: December 17, 2025
Intervention Type: Biological, Drug, Procedure, Radiation
Study Drugs: Carboplatin, Ipilimumab, Nivolumab, Paclitaxel
Study Phase: Phase 2/Phase 3
A Phase I Study of Anetumab Ravtansine in Combination With Either Anti-PD-1 Antibody, or Anti-CTLA4 and Anti-PD-1 Antibodies or Anti-PD-1 Antibody and Gemcitabine in Mesothelin-Positive Advanced Pancreatic Adenocarcinoma
A Phase I Study of Anetumab Ravtansine in Combination With Either Anti-PD-1 Antibody, or Anti-CTLA4 and Anti-PD-1 Antibodies or Anti-PD-1 Antibody and Gemcitabine in Mesothelin-Positive Advanced Pancreatic Adenocarcinoma
Enrollment Status: Active_not_recruiting
Publish Date: September 15, 2025
Intervention Type: Biological, Procedure, Drug
Study Drugs: Anetumab ravtansine, Gemcitabine hydrochloride, Ipilimumab, Nivolumab
Study Phase: Phase 1
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: March 19, 2025
Intervention Type: Drug
Study Drugs: TAK-700, Bicalutamide
Study Phase: Phase 3
Randomized Study of Early Palliative Care Integrated With Standard Oncology Care Versus Standard Oncology Care Alone in Patients With Incurable Lung or Non-Colorectal Gastrointestinal Malignancies
Randomized Study of Early Palliative Care Integrated With Standard Oncology Care Versus Standard Oncology Care Alone in Patients With Incurable Lung or Non-Colorectal Gastrointestinal Malignancies
Enrollment Status: Completed
Publish Date: February 07, 2025
Intervention Type: Other
Study Phase: Phase 3
A Phase 3, Randomized, Double-Blind Study of Pamrevlumab or Placebo in Combination With Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX as Neoadjuvant Treatment in Patients With Locally Advanced, Unresectable Pancreatic Cancer
A Phase 3, Randomized, Double-Blind Study of Pamrevlumab or Placebo in Combination With Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX as Neoadjuvant Treatment in Patients With Locally Advanced, Unresectable Pancreatic Cancer
Enrollment Status: Completed
Publish Date: November 05, 2024
Intervention Type: Drug
Study Drugs: Pamrevlumab, Gemcitabine, Nab-paclitaxel, FOLFIRINOX
Study Phase: Phase 3
A Phase II Study Evaluating Safety and Efficacy of Durvalumab (MEDI4736) Following Multi-modality Therapy in Esophageal Cancer: Big Ten Cancer Research Consortium BTCRC-ESO14-012
A Phase II Study Evaluating Safety and Efficacy of Durvalumab (MEDI4736) Following Multi-modality Therapy in Esophageal Cancer: Big Ten Cancer Research Consortium BTCRC-ESO14-012
Enrollment Status: Completed
Publish Date: September 25, 2023
Intervention Type: Drug
Study Drug: Durvalumab
Study Phase: Phase 2
A Phase 1b Study: Treatment of Refractory Pancreatic Adenocarcinoma and Advanced Soft Tissue or Bone Sarcomas Using Decitabine Combined With Gemcitabine
A Phase 1b Study: Treatment of Refractory Pancreatic Adenocarcinoma and Advanced Soft Tissue or Bone Sarcomas Using Decitabine Combined With Gemcitabine
Enrollment Status: Completed
Publish Date: July 28, 2023
Intervention Type: Drug
Study Drugs: Decitabine, Gemcitabine
Study Phase: Phase 1
View 7 Less Clinical Trials

18 Total Publications

First-line gemcitabine plus nab-paclitaxel versus FOLFIRINOX for metastatic pancreatic cancer in a real-world population.
First-line gemcitabine plus nab-paclitaxel versus FOLFIRINOX for metastatic pancreatic cancer in a real-world population.
Journal: Future oncology (London, England)
Published: May 17, 2022
View All 18 Publications
Similar Doctors
Distinguished in Adult Soft Tissue Sarcoma
Dr. Hans J. Hammers
Oncology
Distinguished in Adult Soft Tissue Sarcoma
Dr. Hans J. Hammers
Oncology

University Of Texas Southwestern Medical Center At Dallas

2201 Inwood Rd, 
Dallas, TX 
 (4.3 miles away)
214-645-2700
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Hans Hammers is an Oncologist in Dallas, Texas. Dr. Hammers is rated as an Elite provider by MediFind in the treatment of Adult Soft Tissue Sarcoma. His top areas of expertise are Renal Cell Carcinoma (RCC), Chromophobe Renal Cell Carcinoma, Wilms Tumor, Nephrectomy, and Thrombectomy.

Distinguished in Adult Soft Tissue Sarcoma
Dr. Eric S. Nadler
Oncology
Distinguished in Adult Soft Tissue Sarcoma
Dr. Eric S. Nadler
Oncology

Texas Oncology, P.A.

3410 Worth Street, Suite 400, 
Dallas, TX 
 (0.1 miles away)
972-449-0540
Experience:
26+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Eric Nadler is an Oncologist in Dallas, Texas. Dr. Nadler has been practicing medicine for over 26 years and is rated as a Distinguished provider by MediFind in the treatment of Adult Soft Tissue Sarcoma. His top areas of expertise are Lung Cancer, Adenoid Cystic Carcinoma, Bone Tumor, and Pleuropulmonary Blastoma.

Advanced in Adult Soft Tissue Sarcoma
Dr. Nayyar T. Syed
Oncology | Hospital Medicine | Hematology
Advanced in Adult Soft Tissue Sarcoma
Dr. Nayyar T. Syed
Oncology | Hospital Medicine | Hematology

Texas Oncology PA

7777 Forest Ln, Suite D110, 
Dallas, TX 
 (8.6 miles away)
972-566-7031
Languages Spoken:
English, Arabic
See accepted insurances
Accepting New Patients
Offers Telehealth

Nayyar Syed is an Oncologist and a Hospital Medicine provider in Dallas, Texas. Dr. Syed is rated as a Distinguished provider by MediFind in the treatment of Adult Soft Tissue Sarcoma. His top areas of expertise are Pleuropulmonary Blastoma, Lung Cancer, Small Cell Lung Cancer (SCLC), and Bone Tumor. Dr. Syed is currently accepting new patients.

VIEW MORE ADULT SOFT TISSUE SARCOMA DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Abushahin's expertise for a condition
ConditionClose
    • Distinguished
    • Familial Pancreatic Cancer
      Dr. Abushahin is
      Distinguished
      . Learn about Familial Pancreatic Cancer.
      See more Familial Pancreatic Cancer experts
    • Pancreatic Cancer
      Dr. Abushahin is
      Distinguished
      . Learn about Pancreatic Cancer.
      See more Pancreatic Cancer experts
    • Advanced
    • Ampullary Cancer
      Dr. Abushahin is
      Advanced
      . Learn about Ampullary Cancer.
      See more Ampullary Cancer experts
    • Cholangiocarcinoma (Bile Duct Cancer)
      Dr. Abushahin is
      Advanced
      . Learn about Cholangiocarcinoma (Bile Duct Cancer).
      See more Cholangiocarcinoma (Bile Duct Cancer) experts
    • Colorectal Cancer
      Dr. Abushahin is
      Advanced
      . Learn about Colorectal Cancer.
      See more Colorectal Cancer experts
    • Familial Colorectal Cancer
      Dr. Abushahin is
      Advanced
      . Learn about Familial Colorectal Cancer.
      See more Familial Colorectal Cancer experts
    • Lynch Syndrome
      Dr. Abushahin is
      Advanced
      . Learn about Lynch Syndrome.
      See more Lynch Syndrome experts
    • Pancreatic Ductal Adenocarcinoma
      Dr. Abushahin is
      Advanced
      . Learn about Pancreatic Ductal Adenocarcinoma.
      See more Pancreatic Ductal Adenocarcinoma experts
    View All 8 Advanced Conditions
    • Experienced
    • Adult Soft Tissue Sarcoma
      Dr. Abushahin is
      Experienced
      . Learn about Adult Soft Tissue Sarcoma.
      See more Adult Soft Tissue Sarcoma experts
    • Alveolar Soft Part Sarcoma
      Dr. Abushahin is
      Experienced
      . Learn about Alveolar Soft Part Sarcoma.
      See more Alveolar Soft Part Sarcoma experts
    • Anal Cancer
      Dr. Abushahin is
      Experienced
      . Learn about Anal Cancer.
      See more Anal Cancer experts
    • Angiosarcoma
      Dr. Abushahin is
      Experienced
      . Learn about Angiosarcoma.
      See more Angiosarcoma experts
    • Bone Tumor
      Dr. Abushahin is
      Experienced
      . Learn about Bone Tumor.
      See more Bone Tumor experts
    • Epithelioid Sarcoma
      Dr. Abushahin is
      Experienced
      . Learn about Epithelioid Sarcoma.
      See more Epithelioid Sarcoma experts
    View All 28 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile
    For Patients
    • Our Story
    • How MediFind Works
    • Conditions A-Z
    • Doctor Directory
    • Symptoms Directory
    • Procedures Directory
    • Treatment Directory
    • Drug Directory
    • Infusion Center Finder
    • FAQ
    • Contact Us
    For Providers and Practices
    • Claim Your Profile
    • Newsroom
    Business Solutions
    • Provider
    • Network Solutions
    Additional Resources
    • Consumer Health Data Privacy Policy
    • Privacy Policy
    • Terms of Use
    • Advertising Policy
    • Content Policy
    Subscribe to our newsletter

    Sign up to stay informed about MediFind and get wellness sent your way.

    Close

      By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

      Bullet PinMediFind
      Follow us on
      This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
      © 2026 All Rights Reserved

      Request an Appointment

      If you are experiencing a medical emergency, call 9-1-1.

      MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

      Patient Details

      This information is for the patient who will be seen at the appointment.

        Close

        Returning patient? Use your address on file with the provider.

        Insurance Details

        Please provide information of the primary insurance holder as the practice may require this information to schedule.

        Insurance Provider *
        Insurance ProviderClose

        Appointments Details

        Let’s get more information about your appointment.

                0 / 1000
                0 / 1000
                By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.